[HTML][HTML] Phase I results from a study of crizotinib in combination with erlotinib in patients with advanced nonsquamous non–small cell lung cancer
SHI Ou, R Govindan, KD Eaton, GA Otterson… - Journal of Thoracic …, 2017 - Elsevier
Introduction This phase I trial was conducted to determine the safety, maximum tolerated
dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients …
dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients …
[PDF][PDF] Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
GA Otterson - J Thorac Oncol, 2017 - researchgate.net
Introduction: This phase I trial was conducted to determine the safety, maximum tolerated
dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients …
dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients …
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.
SI Ou, R Govindan, KD Eaton, GA Otterson… - Journal of Thoracic …, 2016 - europepmc.org
Methods Patients with NSCLC and an Eastern Cooperative Oncology Group performance
status of 0 to 2 after failure of one or two prior chemotherapy regimens were eligible …
status of 0 to 2 after failure of one or two prior chemotherapy regimens were eligible …
[HTML][HTML] Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
SHI Ou, R Govindan, KD Eaton… - Journal of thoracic …, 2017 - ncbi.nlm.nih.gov
Methods: Patients with NSCLC and an Eastern Cooperative Oncology Group performance
status of 0 to 2 after failure of one or two prior chemotherapy regimens were eligible …
status of 0 to 2 after failure of one or two prior chemotherapy regimens were eligible …
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer
SHI Ou, R Govindan, KD Eaton… - Journal of …, 2017 - ohiostate.elsevierpure.com
Introduction This phase I trial was conducted to determine the safety, maximum tolerated
dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients …
dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients …
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
SHI Ou, R Govindan, KD Eaton… - Journal of thoracic …, 2017 - pubmed.ncbi.nlm.nih.gov
Introduction This phase I trial was conducted to determine the safety, maximum tolerated
dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients …
dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients …
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer
SHI Ou, R Govindan, KD Eaton… - Journal of Thoracic …, 2017 - profiles.wustl.edu
Introduction This phase I trial was conducted to determine the safety, maximum tolerated
dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients …
dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients …
[HTML][HTML] Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer
SHI Ou, R Govindan, KD Eaton, GA Otterson… - Journal of Thoracic …, 2017 - jto.org
Introduction This phase I trial was conducted to determine the safety, maximum tolerated
dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients …
dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients …
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer
SHI Ou, R Govindan, KD Eaton… - Journal of Thoracic …, 2017 - escholarship.org
IntroductionThis phase I trial was conducted to determine the safety, maximum tolerated
dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients …
dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients …